$21.100
+0.264 (+1.25%)At close
ANIK News
ANIK Events
Company Q1 Revenue Grows to $29.6M
Reports Q1 revenue $29.6M vs. $26.2M last year. Reports total company revenue grew 13%, driven by commercial channel strength and favorable OEM channel order timing. "Our strategic transformation and organizational realignment is yielding results and driving improved profitability and efficiencies throughout the organization," said CEO Steve Griffin.
Anika Provides 2026 Guidance of $114M to $122.5M Revenue
Anika is providing the following 2026 guidance: Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year; Commercial Channel, $53 to $58 million, maintaining up 10% to 20% year over year; OEM Channel, $61 to $64.5 million, maintaining flat to modestly lower year over year; Adjusted EBITDA as a percent of revenue to 5% to 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.
Anika Therapeutics Reports Q4 Revenue Flat at $30.6M
Reports Q4 revenue $30.6M vs $30.6M last year. "We closed 2025 with a strong fourth quarter, with top-line growth led by our Commercial Channel and company-wide results that included expanded gross margin, and positive operating income and free cash flow," said Steve Griffin, President and Chief Executive Officer of Anika Therapeutics. "Our operating income performance in the fourth quarter and full year underscores the strength of our core OA Pain Management business despite U.S. pricing headwinds in 2025 and establishes a foundation for improved profitability.
Anika Therapeutics Appoints Stephen Griffin as CEO
Anika Therapeutics announced that Stephen Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Griffin will succeed Cheryl Blanchard, Ph.D., who will become Executive Chair of the Board of Directors. In addition, John Henneman, III, Director since 2020, has been appointed Lead Independent Director.
Anika announces submission of final PMA module for Hylofast cartilage repair.
Anika Therapeutics announced that it filed the third and final module of its Premarket Approval application, PMA, for Hyalofast-its resorbable, hyaluronic acid-based scaffold used with autologous bone marrow aspirate concentrate, BMAC, for treating articular cartilage defects in the knee. The Company also reported results from its U.S. pivotal Phase III FastTRACK clinical trial evaluating Hyalofast. On October 31, 2025, Anika submitted the third and final module of its Hyalofast PMA to the U.S. Food and Drug Administration. The PMA includes FastTRACK 24-month data and incorporates additional post-hoc analyses and real-world data.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.